17h
Hut 8 Focuses On AI Infrastructure Growth, But Operating Profitability Is Still A Work In Progress
Q4 results underscore Hut 8's dependence on bitcoin price movements, with digital asset losses driving a sharp swing. Check ...
Analysts have set 12-month price targets for Kymera Therapeutics, revealing an average target of $123.41, a high estimate of $140.00, and a low estimate of $103.00. This upward trend is evident, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results